CRISPR Therapeutics AG (CRSP) Operating Income: 2015-2025
Historic Operating Income for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -$132.1 million.
- CRISPR Therapeutics AG's Operating Income fell 19.91% to -$132.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$574.4 million, marking a year-over-year decrease of 72.81%. This contributed to the annual value of -$466.6 million for FY2024, which is 109.66% down from last year.
- According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Operating Income is -$132.1 million, which was up 42.41% from -$229.3 million recorded in Q2 2025.
- CRISPR Therapeutics AG's Operating Income's 5-year high stood at $762.6 million during Q2 2021, with a 5-year trough of -$229.3 million in Q2 2025.
- Moreover, its 3-year median value for Operating Income was -$132.1 million (2025), whereas its average is -$109.0 million.
- In the last 5 years, CRISPR Therapeutics AG's Operating Income surged by 1,045.13% in 2021 and then crashed by 192.82% in 2024.
- Over the past 5 years, CRISPR Therapeutics AG's Operating Income (Quarterly) stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then surged by 152.90% to $69.6 million in 2023, then slumped by 192.82% to -$64.6 million in 2024, then decreased by 19.91% to -$132.1 million in 2025.
- Its Operating Income was -$132.1 million in Q3 2025, compared to -$229.3 million in Q2 2025 and -$148.4 million in Q1 2025.